CTLA4 and melanoma: Another recent multicenter retrospective analysis investigated the retreatment with BRAFi and MEKi combination in 51 patients with metastatic BRAF-mutated melanoma, previously progressed after receiving kinase inhibitors (BRAFi and MEKi or BRAFi alone) and immunotherapy (anti-PD-1 or anti-CTLA-4) (16).